Lean oncology: a new model for oncologists

por Montesarchio, Vincenzo, Grimaldi, Antonio Maria, Fox, Bernard A, Rea, Antonio, Marincola, Francesco M, Ascierto, Paolo A
Publicado 2012

Do BRAF inhibitors select for populations with different disease progression kinetics?

por Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Publicado 2013

Serious haematological toxicity during and after ipilimumab treatment: a case series

por Simeone, Ester, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Palla, Marco, Paone, Miriam, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado 2014

Pancreatic Cancer: Beyond Brca Mutations

por Ricci, Vincenzo, Fabozzi, Teresa, Bareschino, Maria Anna, Barletta, Emiddio, Germano, Domenico, Paciolla, Immacolata, Tinessa, Vincenza, Grimaldi, Antonio Maria
Publicado 2022

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

por Stucci, Stefania, Tucci, Marco, Ascierto, Paolo Antonio, Passarelli, Anna, Mariaelena, Capone, Madonna, Gabriele, Ester, Simeone, Grimaldi, Antonio Maria, Silvestris, Franco
Publicado 2015

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series

por Di Monta, Gianluca, Caracò, Corrado, Marone, Ugo, Grimaldi, Antonio Maria, Anniciello, Anna Maria, Di Marzo, Massimiliano, Simeone, Ester, Mori, Stefano
Publicado 2015

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

por Montella, Maurizio, Gandini, Sara, Rossi, Carlo Riccardo, Testori, Alessandro, Mastrangelo, Giuseppe, Serraino, Diego, Budroni, Mario, Crispo, Anna, Grimaldi, Antonio Maria, Ascierto, Paolo Antonio
Publicado 2014

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report

por Falivene, Sara, Giugliano, Francesca Maria, Grimaldi, Antonio Maria, Di Franco, Rossella, Toledo, Diego, Muto, Matteo, Cammarota, Fabrizio, Borzillo, Valentina, Ascierto, Paolo Antonio, Muto, Paolo
Publicado 2014

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

por Grimaldi, Antonio Maria, Simeone, Ester, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Publicado 2015

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

por Simeone, Ester, Benedetto, Lucia, Gentilcore, Giusy, Capone, Marilena, Caracò, Corrado, Di Monta, Gianluca, Marone, Ugo, Di Cecilia, Marialuisa, Grimaldi, Antonio Maria, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo A
Publicado 2014

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

por Di Monta, Gianluca, Caracò, Corrado, Simeone, Ester, Grimaldi, Antonio Maria, Marone, Ugo, Di Marzo, Massimiliano, Vanella, Vito, Festino, Lucia, Palla, Marco, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado 2017

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

por Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe, Cavalcanti, Ernesta, Caracò, Corrado, Ascierto, Paolo Antonio
Publicado 2018

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

por Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Rinaldi, Giovanni, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Publicado 2015

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

por Queirolo, Paola, Spagnolo, Francesco, Picasso, Virginia, Spano, Laura, Tanda, Enrica, Fontana, Valeria, Giorello, Laura, Merlo, Domenico Franco, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Del Vecchio, Michele, Bruzzi, Paolo, Ascierto, Paolo Antonio
Publicado 2016

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma

por Scognamiglio, Giosuè, Capone, Mariaelena, Sabbatino, Francesco, Di Mauro, Annabella, Cantile, Monica, Cerrone, Margherita, Madonna, Gabriele, Grimaldi, Antonio Maria, Mallardo, Domenico, Palla, Marco, Sarno, Sabrina, Anniciello, Anna Maria, Di Bonito, Maurizio, Ascierto, Paolo Antonio, Botti, Gerardo
Publicado 2021

Clinical trials and drug cost savings for Italian health service

por D’Ambrosio, Francesca, De Feo, Gianfranco, Botti, Gerardo, Capasso, Arturo, Pignata, Sandro, Maiolino, Piera, Triassi, Maria, Nardone, Antonio, Perrone, Franco, Piezzo, Michela, Grimaldi, Antonio Maria, Palazzo, Ida, De Stasio, Immacolata, D’Aniello, Roberta, Morabito, Alessandro, Pascarella, Giacomo
Publicado 2020

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

por Daponte, Antonio, Signoriello, Simona, Maiorino, Luigi, Massidda, Bruno, Simeone, Ester, Grimaldi, Antonio Maria, Caracò, Corrado, Palmieri, Giuseppe, Cossu, Antonio, Botti, Gerardo, Petrillo, Antonella, Lastoria, Secondo, Cavalcanti, Ernesta, Aprea, Pasquale, Mozzillo, Nicola, Gallo, Ciro, Comella, Giuseppe, Ascierto, Paolo Antonio
Publicado 2013

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evide...

por Madonna, Gabriele, Masucci, Giuseppe V., Capone, Mariaelena, Mallardo, Domenico, Grimaldi, Antonio Maria, Simeone, Ester, Vanella, Vito, Festino, Lucia, Palla, Marco, Scarpato, Luigi, Tuffanelli, Marilena, D’angelo, Grazia, Villabona, Lisa, Krakowski, Isabelle, Eriksson, Hanna, Simao, Felipe, Lewensohn, Rolf, Ascierto, Paolo Antonio
Publicado 2021

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

por Simeone, Ester, Romano, Maria fiammetta, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Paone, Miriam, Rinaldi, Giovanni, Di monta, Gianluca, Di marzo, Massimiliano, Hauber, Federica, Festino, Lucia, D'Angelillo, Anna, Romano, Simona, Staibano, Stefania, Ilardi, Gennaro, Bisogni, Rita, Mozzillo, Nicola, Ascierto, Paolo Antonio
Publicado 2014

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

por Chiarion Sileni, Vanna, Pigozzo, Jacopo, Ascierto, Paolo Antonio, Grimaldi, Antonio Maria, Maio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, de Rosa, Francesco, Nuzzo, Carmen, Testori, Alessandro, Cocorocchio, Emilia, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Merelli, Barbara, Parmiani, Giorgio, Rinaldi, Gaetana, Aglietta, Massimo, Grosso, Marco, Queirolo, Paola
Publicado 2014